Specify a stock or a cryptocurrency in the search bar to get a summary
Inhibikase Therapeutics Inc
IKTInhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia. Address: 3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339
Analytics
WallStreet Target Price
6.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures IKT
Dividend Analytics IKT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IKT
Stock Valuation IKT
Financials IKT
Results | 2019 | Dynamics |